Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.35 |
| ▸ | MGMT | P16455 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20497218 | 0.91 | CDK1 (0.36) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL2113440 | 0.84 | ADORA2A (0.41) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL15013384 | 0.84 | MEN1 (0.40) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL5664376 | 0.82 | PDE4A (0.39) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL7586877 | 0.81 | PNP (0.47) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL7617801 | 0.80 | ADORA2A (0.40) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7173171 | 0.79 | ADORA2A (0.40) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8423728 | 0.79 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DCDK1 | |
| SCHEMBL27842808 | 0.79 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL28071828 | 0.78 | PNP (0.45) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2120966-A2 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | Enzon Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008070477-A2 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139496-A1 | COMBINATION THERAPY FOR REDUCTION OF TOXICITY OF CHEMOTHERAPEUTIC AGENTS | CASCADE ESTATE LTD. (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20070105790-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105789-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060135441-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060135468-A1 | Treatment of refractory cancers using NA+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-20060135442-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| US-5646179-A | VIRICIDES FOR RETROVIRAL DISEASE TREATMENT | ANALYTICON GESELLSCHAFT FUR CHEMISCHE ANALYTIK UND CONSULTING GMBH (DE) | 1997-07-08 | — | — | US | disclosed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5321030-A | Administering for treatment or prevention | AMIRA, INC. (US) | 1994-06-14 | — | — | US | disclosed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0312222-B1 | TREATMENT OF DISEASES CAUSED BY VIRUSES | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-4931575-A | Chiral glycerol derivatives | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0312222-A1 | Treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0270317-A2 | Pharmaceutical compositions for the treatment of diseases caused by viruses | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135468-A1 | Treatment of refractory cancers using NA+/K+ ATPase inhibitors | ATP1A4, ATP1B1, ATP1A2 | PDE4A 471/4885PDE4B 342/4885PDE4C 612/4885 |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | SNRPE, RNASE1, PHAX | PDE4A 4092/4885PDE4B 4016/4885PDE4C 3851/4885 |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | ATP1A4, ATP1A3, ATP1B3 | PDE4A 475/4885PDE4B 550/4885PDE4C 675/4885 |
| US-20070105789-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1A3, HIF1AN | PDE4A 512/4885PDE4B 514/4885PDE4C 797/4885 |
| US-20060135442-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1B1, ATP1A1 | PDE4A 230/4885PDE4B 152/4885PDE4C 341/4885 |
| US-20070105790-A1 | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors | ATP1A4, ATP1A3, ATP1A1 | PDE4A 378/4885PDE4B 361/4885PDE4C 602/4885 |
| US-20060135441-A1 | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors | ATP1A1, HIF1AN, ATP1A4 | PDE4A 633/4885PDE4B 475/4885PDE4C 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.